# Sensation, Motion, and Quality of Life on Natalizumab and Off Natalizumab

> **NCT05172466** · NA · WITHDRAWN · sponsor: **Icahn School of Medicine at Mount Sinai**

## Conditions studied

- Relapsing-remitting Multiple Sclerosis (RRMS)

## Interventions

- **DEVICE:** BeCare application

## Key facts

- **NCT ID:** NCT05172466
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-10-31
- **Primary completion:** 2022-11-11
- **Final completion:** 2022-11-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack on enrollment
- **Last updated:** 2022-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05172466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05172466, "Sensation, Motion, and Quality of Life on Natalizumab and Off Natalizumab". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05172466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*